08:36 AM EST, 12/09/2024 (MT Newswires) -- AngioDynamics ( ANGO ) said Monday its NanoKnife System received 510(k) clearance from the US Food and Drug Administration for prostate tissue ablation.

The clearance was based on the company's Preserve clinical study and submission of results to the regulator in September, which evaluated NanoKnife's safety and effectiveness in participants with intermediate-risk prostate cancer, AngioDynamics ( ANGO ) said.

The trial results demonstrated a "robust safety and clinical efficacy" profile of the system, the medical technology company said.

Shares of AngioDynamics ( ANGO ) were up 5.7% in recent premarket activity.